Showing 2921-2930 of 3039 results for "".
- Joe Garibaldi Appointed Vice President of US Sales at Optovuehttps://modernod.com/news/joe-garibaldi-appointed-vice-president-of-us-sales-at-optovue/2476172/Joe Garibaldi has been appointed to vice president of US Sales at Optovue, where he will continue to lead the US sales force as well as identify new strategic partnering opportunities to grow the company’s US product portfolio. Garibaldi joined Optovue in 2009 as a territory manager and he
- DORC Unveils Enhancements to the EVA Phacovitrectomy Systemhttps://modernod.com/news/dorc-unveils-enhancements-to-the-eva-phacovitrectomy-system/2476178/DORC has announced the launch several enhancements to its EVA surgical system aimed at delivering both operating room efficiency and surgical performance. The enhancements include a new EVA footswitch that been completely redesigned. Control of the EVA endolaser is now integrated into the
- Aerpio Pharmaceuticals Completes Patient Dosing in TIME-2b Study of AKB-9778 in Diabetic Retinopathyhttps://modernod.com/news/aerpio-pharmaceuticals-completes-patient-dosing-in-time-2b-study-of-akb-9778-in-diabetic-retinopathy/2476181/Aerpio Pharmaceuticals announced the completion of patient dosing in the company’s TIME-2b study, a phase 2b clinical trial designed to assess the efficacy and safety of Aerpio’s lead candidate, AKB-9778, for patients with moderate to severe nonproliferative diabetic retinopathy (NPDR). &#
- Aerie Pharmaceuticals Announces Acceptance of Its Investigational NDA for AR-1105 (Dexamethasone Intravitreal Implant)https://modernod.com/news/aerie-pharmaceuticals-announces-acceptance-of-its-investigational-nda-for-ar-1105-dexamethasone-intravitreal-implant/2476183/Aerie Pharmaceuticals announced that the FDA has reviewed the investigational new drug application (IND) for AR-1105 (dexamethasone intravitreal implant) and it is now in effect, allowing Aerie to initiate human studies in the treatment of macular edema due to retinal vein occlusion (RVO). The IN
- Atlantic Street Capital Forms Advancing Eyecare Holdings With Partnership of Lombart Instrument and Marco Ophthalmichttps://modernod.com/news/atlantic-street-capital-forms-advancing-eyecare-holdings-with-partnership-of-lombart-instrument-and-marco-ophthalmic/2476196/Private equity firm Atlantic Street Capital announced that it will form Advancing Eyecare Holdings with the partnership of its portfolio company Lombart Instrument, a distributor of ophthalmic instruments, and Marco Ophthalmic, an instrumentation supplier. Terms of the deal were not disclo
- FDA Approved Record Number of Drugs in 2018https://modernod.com/news/fda-approved-record-number-of-drugs-in-2018/2476204/Last year was a banner year for the FDA, with 59 new drugs approved by the Center for Drug Evaluation and Research (CDER), including 19 first-in-class agents, 34 novel drugs for rare diseases, and a record seven biosimilars, according to a rep
- CooperVision Acquires Blanchard Contact Lenses, Expanding Presence in Specialty Segmenthttps://modernod.com/news/coopervision-acquires-blanchard-contact-lenses-expanding-presence-in-specialty-segment/2476206/CooperVision has acquired Blanchard Contact Lenses, a maker of scleral lenses. Terms of the deal were not disclosed. Blanchard, with its network of distributors, operates in North America, Europe (including Scandinavia), Central America, and South America. Its recently introduced On
- EyeQue Announces Availability of PDCheck on Kickstarter Websitehttps://modernod.com/news/eyeque-announces-availability-of-pdcheck-on-kickstarter-website/2476210/EyeQue, which develops at-home vision tests for smartphones, said this week that its PDCheck tool, a method for measuring pupillary distance (PD), is now available on Kickstarter, according to a
- Healthe Named One of the Nation’s 20 Hottest Health Start-Upshttps://modernod.com/news/healthe-named-one-of-the-nations-20-hottest-health-start-ups/2476213/Healthe, an eye health company that develops products and technology to block ultra-violet and high-energy visible blue light, announced that it was selected by THE OBSERVER as one of the nation’s hottest digital health companies. The list focuses on non-coastal, start-ups from the Midwest, South
- ProQR Reaches Agreement with the FDA on Design of Phase 2/3 Pivotal Trial for Sepofarsen (QR-110) for Leber’s Congenital Amaurosis 10https://modernod.com/news/proqr-reaches-agreement-with-the-fda-on-design-of-phase-2-3-pivotal-trial-for-sepofarsen-qr-110-for-lebers-congenital-amaurosis-10/2476214/ProQR Therapeutics announced that it has reached agreement with the FDA on the design of a phase 2/3 pivotal trial (ILLUMINATE) for QR-110, now renamed to sepofarsen, in patients with Leber’s congenital amaurosis 10 (LCA10) due to the p.Cys998X mutation in the CEP290gene. LCA is the lead